Literature DB >> 27816027

Cognitive impairment in patients with Parkinson's disease: A 30-month follow-up study.

Ling Chen1, Cuiyu Yu2, Ning Zhang3, Junjun Liu4, Weiguo Liu5.   

Abstract

OBJECTIVE: A longitudinal (30-month) study of the cognitive changes in Parkinson's disease patients and analysis of influencing factors.
METHODS: The cognitive function and related symptoms of 102 patients with idiopathic Parkinson's disease were assessed using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), and relevant scales, at baseline and 30-month follow-up. The t-test, nonparametric tests, and regression analyses were used to evaluate cognitive decline and investigate risk factors for cognitive impairment.
RESULTS: From baseline to follow-up, the MMSE and MoCA scores significantly decreased, respectively, from 28.16±2.29 to 26.18±3.64, and from 24.60±4.23 to 21.94±5.47 (both P<0.001). Impairment was observed in multiple cognitive areas, significantly in naming, delayed recall, and orientation (P<0.01). Patients at baseline with postural instability and gait disturbance (PIGD), lower MoCA scores, or depression had a higher risk of cognitive impairment at follow-up (P<0.01).
CONCLUSION: Cognitive impairment is highly prevalent in Parkinson's disease patients, especially for those with lower MoCA scores, PIGD, and depression. Copyright Â
© 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Cognitive impairment; Follow-up; Mini-mental state examination; Montreal cognitive assessment (MoCA); Parkinson's disease

Mesh:

Year:  2016        PMID: 27816027     DOI: 10.1016/j.clineuro.2016.09.021

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

Review 1.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

2.  Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Authors:  Achinoam Faust-Socher; Sarah Duff-Canning; Arthur Grabovsky; Melissa J Armstrong; Brandon Rothberg; Paul J Eslinger; Christopher A Meaney; Ruth B Schneider; David F Tang-Wai; Susan H Fox; Cindy Zadikoff; Nancy Kennedy; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; William Reginold; Connie Marras
Journal:  Dement Geriatr Cogn Disord       Date:  2019-07-17       Impact factor: 2.959

3.  White matter alterations in Parkinson's disease with normal cognition precede grey matter atrophy.

Authors:  Ivan Rektor; Alena Svátková; Lubomir Vojtíšek; Iva Zikmundová; Jirí Vaníček; András Király; Nikoletta Szabó
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

4.  Resting State fMRI Reveals Increased Subthalamic Nucleus and Sensorimotor Cortex Connectivity in Patients with Parkinson's Disease under Medication.

Authors:  Bo Shen; Yang Gao; Wenbin Zhang; Liyu Lu; Jun Zhu; Yang Pan; Wenya Lan; Chaoyong Xiao; Li Zhang
Journal:  Front Aging Neurosci       Date:  2017-04-04       Impact factor: 5.750

5.  Research on depression in Parkinson disease: A bibliometric and visual analysis of studies published during 2012-2021.

Authors:  Yan Liu; Linlin Ding; Yunyan Xianyu; Shuke Nie; Jiying Yang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

Review 6.  Transcranial Current Stimulation as a Tool of Neuromodulation of Cognitive Functions in Parkinson's Disease.

Authors:  Ivan V Brak; Elena Filimonova; Oleg Zakhariya; Rustam Khasanov; Ivan Stepanyan
Journal:  Front Neurosci       Date:  2022-07-12       Impact factor: 5.152

7.  Synergistic Effects of Aldehyde Dehydrogenase 2 Polymorphisms and Alcohol Consumption on Cognitive Impairment after Ischemic Stroke in Han Chinese.

Authors:  Ying Yu; Jie Gao; Shasha Wang; Heng Lv; Liping Xiao; Hengyuan Shi; Xianjie Jia
Journal:  Behav Neurol       Date:  2021-06-24       Impact factor: 3.342

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.